The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Silke AppenzellerAnja GesierichAlexander ThiemAnita HufnagelChristina JessenHermann KneitzMartina RegensburgerCornelia SchmidtVanessa ZirkenbachThorsten BischlerBastian SchillingClaudia SiedelMaria-Elisabeth GoebelerRoland HoubenDavid SchramaAndrea GehrigSimone RostKatja MaurusRalf BargouAndreas RosenwaldManfred SchartlMatthias GoebelerSvenja MeierjohannPublished in: Cancer (2018)
The results indicate that the integrated analysis of SNVs, CNVs, and germline mutations reveals new druggable targets for combination tumor therapy.